Trials / Not Yet Recruiting
Not Yet RecruitingNCT07083505
A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer
A Multicenter, Randomized, Open-Label Phase II Clinical Trial Comparing Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, open-label, multicenter Phase II clinical trial evaluating the efficacy and safety of HB1801 compared with Taxotere® in patients with advanced breast cancer. A total of 60 subjects with advanced breast cancer are planned to be enrolled.The trial consists of three phases: screening period, open-label treatment period, and follow-up period. HB1801 is Docetaxel for injection (Albumin-bound).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HB1801 | HB1801 \[administered according to the clinical trial protocol\] |
| DRUG | Taxotere® | Taxotere® 75 mg/ m\^2 \[administered according to the clinical trial protocol\]\] |
Timeline
- Start date
- 2025-08-15
- Primary completion
- 2026-10-11
- Completion
- 2026-12-31
- First posted
- 2025-07-24
- Last updated
- 2025-07-24
Source: ClinicalTrials.gov record NCT07083505. Inclusion in this directory is not an endorsement.